Peripheral Drug Eluting Balloons Market

Peripheral Drug Eluting Balloons Market Outlook (2023 to 2033)

The global peripheral drug eluting balloons market expanded at a CAGR of 6% in the last 10 years and stood at US$ 808.2 million in 2022. The market is predicted to surge ahead at 8.6% CAGR and reach a valuation of US$ 1.9 billion by the end of 2033.

Peripheral drug-eluting balloons (DEBs) are medical devices used in interventional cardiology and other fields to treat various cardiovascular conditions, particularly arterial blockages or stenosis. DEBs combine the mechanical dilatation of balloon angioplasty with the local delivery of medication to the site of the lesion.

• This study by Persistence Market Research reveals that paclitaxel drug coating held a market share of 47.8% in 2022.
• Peripheral drug eluting balloon sales accounted for 17.2% revenue share of the global peripheral vascular devices market in 2022.

The narrowing or obstruction of the blood arteries that travel from the heart to the limbs is known as peripheral vascular disease. The accumulation of fatty plaque in arteries is the main cause of this condition. The market is expanding mainly as a result of an increase in the incidence of peripheral arterial disease across the world.

• According to the National Institutes of Health, in 2020, due to alterations in lifestyle habits, smoking, pollution, and other causes, the illness claimed the lives of 20% of persons 55 years of age and older.

Development of the market for peripheral drug eluting balloons market is likely to be fueled by increased attention being paid to the prevention and treatment of peripheral arterial disease in low- and middle-income countries. Demand for interventional cardiology care is rising as peripheral arterial disease is becoming more common. Angioplasty is the first choice of treatment for patients with long-term PAD.

• According to the Centers for Disease Control and Prevention (CDC), in 2021, around 8.5 million people in the U.S. were suffering from PAD, including 12% to 20% of individuals older than 60 years.

All in all, increasing prevalence of peripheral arterial disease and growing healthcare expenditure in lower-middle-income countries are projected to boost the growth of the global peripheral drug eluting balloons market over the coming years.

Why is the Usage of Peripheral Drug Eluting Balloons Increasing So Fast?

“Rising Aging Population and Increasing Prevalence of Vascular Diseases”

The geriatric population is more prone to vascular diseases due to natural aging, further contributing to the increasing demand for peripheral vascular surgeries. Growing requirement for stents during surgeries among the geriatric population, coupled with improved life expectancies, has created enormous opportunities for manufacturers.

• According to the United Nations, in 2019, middle-income countries are expecting rapid growth in the number of older persons between 2015 and 2030. In India, for example, the number of aging people is projected to grow by 64 percent between 2015 and 2030, while the same in China it is projected to grow by 71 percent. Furthermore, according to the World Health Organization, there will be 2 billion older individuals around the world by the year 2050, up from 900 million in 2015.
• The population of Americans who are 65 and older is expected to more than double from 46 million to over 98 million by 2060, according to the Population Reference Bureau, 2023, and their proportion of the overall population will increase from 15% to almost 24%.

What are the Issues being Faced by Market Players?

“High Product Cost and Limited Clinical Evidence”

Peripheral drug eluting balloons can be relatively expensive compared to traditional treatment options such as angioplasty or stenting. Higher upfront costs associated with DEBs, including the cost of the device and drug, can be a deterrent to their adoption, particularly in regions with limited healthcare budgets or reimbursement constraints. Cost of DEBs compared to alternative treatments remains an ongoing consideration for healthcare providers and payers.

Although DEBs have shown promising results in clinical studies, there is still a need for robust long-term clinical evidence to demonstrate their efficacy and superiority over alternative treatments. Limited availability of long-term data on patient outcomes and lack of large-scale randomized controlled trials can impact the confidence of healthcare providers in adopting DEBs as a standard treatment option.

Country-wise Insights

What Makes the United States a Prominent Market for Peripheral Drug Eluting Balloons?

“Increasing Prevalence of Peripheral Artery Disease in the Country”

The U.S. accounted for 36.2% share of the global market in 2022.

The U.S. market for peripheral drug eluting balloons is forecasted to expand significantly owing to the manufacturing and development of advanced products and increasing prevalence of peripheral artery diseases in the country.

Rising prevalence of the disease is a significant driver for the market in the U.S. The country has a substantial population affected by PAD, primarily due to factors such as growing aging population, high prevalence of diabetes, obesity, and lifestyle habits such as smoking.

• According to the U.S. Department of Health & Human Services, 2023, around 6.5 million people age 40 and older are living with PAD in the U.S.

Will China Be a Lucrative Market for Peripheral Drug Eluting Balloon Manufacturers?

“Favorable Government Policies and Reimbursement Support in China”

China held 6.5% share of the global market in 2022.

The Chinese government has been actively promoting healthcare reforms and increasing investments in the healthcare sector. Reforms and policies have aimed to improve access to healthcare services, enhance reimbursement schemes, and reduce the financial burden on patients. Favorable reimbursement policies for peripheral DEBs have encouraged healthcare providers to adopt and utilize these devices on a larger scale, thereby driving market growth.

Chinese medical device manufacturers have been partnering and collaborating with international companies to access advanced technologies, gain expertise, and expand their market reach. These collaborations help bring advanced DEB products into the Chinese market, offering a wider range of treatment options to healthcare providers and patients.

How is Demand for Peripheral Drug Eluting Balloons Shaping Up in Germany?

“Rapidly Increasing Advanced Healthcare Infrastructure”

Germany held a share of 6.3% of the global market in 2022.

Germany is known for its advanced healthcare infrastructure, which facilitates the adoption of innovative medical technologies. The presence of well-equipped hospitals, specialized medical centers, and skilled healthcare professionals creates an environment conducive to the utilization of DEBs.

This advanced healthcare infrastructure has been contributing to the growth of the market in Germany. Awareness and education about peripheral artery disease and available treatment options have been increasing in Germany. Healthcare professionals, patients, and caregivers are becoming more knowledgeable about peripheral DEBs and their potential benefits, which has led to greater product acceptance and adoption.

Category-wise Insights

Which Drug Coating is Driving Demand within the Global Market?

“Paclitaxel Drug Coating Effective in Inhibition of Neointimal Hyperplasia”

The paclitaxel drug coating segment held 47.8% share of the global market in 2022.

Paclitaxel is an antiproliferative drug that inhibits the excessive growth of smooth muscle cells in the arterial wall, known as neointimal hyperplasia. By preventing the formation of excessive tissues within the artery, paclitaxel-coated DEBs help reduce the risk of restenosis (re-narrowing of the artery) and the need for repeat interventions.

Which Indication is a Dominating Factor in This Market?

“Increasing Prevalence of Peripheral Arterial Disease”

Peripheral arterial disease accounted for 37.8% share of the global market in 2022.

Peripheral arterial disease shares common risk factors with other cardiovascular diseases, including smoking, diabetes, hypertension, hyperlipidemia (high cholesterol), and obesity. High prevalence of these risk factors worldwide is contributing to the increasing incidence of peripheral arterial disease.

• According to estimates from the Global Burden of Disease Study, 2021, the global prevalence of PAD increased by around 23.5% between 2000 and 2019. It is projected to continue rising due to population aging and lifestyle factors.

Competition Landscape

The market for peripheral drug eluting balloons has a fair amount of competition. Businesses are putting a lot of effort into growing their presence in emerging markets and preserving their connections with current distributors. The competitive environment includes an analysis of a few global and local businesses that control the market shares.

• In Aug. 2022, BD initiated the first-in-human trial, non-randomized study designed to evaluate the safety of a drug-coated balloon (DCB). The study will determine the viability of sirolimus for treating peripheral arterial disease in the femoropopliteal arteries.
• In June 2018, Terumo acquired CE approval for its drug-coated balloon catheter Kanshas. This catheter will be used for lower extremities peripheral arterial disease.

Similarly, the team at Persistence Market Research has tracked recent developments related to companies in the peripheral drug eluting balloons market, which are available in the full report.

Peripheral Drug Eluting Balloons Industry Report Scope

Key Segments of Peripheral Drug Eluting Balloons Industry Research

Drug Coating:

• Paclitaxel Drug Coating
• Sirolimus drug Coating
• Others

Indication:

• Peripheral Arterial Disease
• Peripheral Aneurysms
• In-Stent Restenosis
• Others

Artery Type:

• Carotid Arteries
• Fem-Pop Arteries
• Iliac Arteries
• Infrapop Arteries

End User:

• Hospitals
• Ambulatory Surgical Centers/Outpatients
• Cardiac Catheterization Labs

Region:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East & Africa

To know more about delivery timeline for this report Contact Sales